We would like to thank the readers for their appreciated comment on our recent article. The primary aim of our retrospective analysis was to assess the feasibility and toxicity e potentially related with intraventricular methotrexate (i.vc. MTX). In addition, we performed several explorative analyses in order to test whether the i.vc. MTX may have an effect on survival. The additional impact of intravenous methotrexate, in terms of doses, leucovorin rescue, etc., was not assessable in this analysis due to the nature of our data retrieved from different trials. As stated in the Discussion, we agree that there might have been a positive selection of those patients who received >75% of scheduled i.vc. MTX and that there are other factors which had an influence on our results, e.g. tumour size, extend of resection, treatment centre, molecular findings, and treatment components (including high-dose methotrexate). However, to reduce the bias of positive selection concerning systemic chemotherapy, the amount of administered i.vc. MTX